Revealed: The bowel cancer breakthrough that could save young sufferers - Daily Mail
A bowel cancer treatment for the aggressive BRAF V600E mutation, similar to Dame Deborah James's case, has been approved for NHS use. The drug combination, trifluridine-tipiracil hydrochloride and bevacizumab, extends life by nearly a year for patients with no other treatment options, with some rare cases gaining up to seven more years. This approval is a significant step in fighting the incurable genetic form of bowel cancer, which often affects the young.
Highlighted Terms
Related News
A bowel cancer treatment for the aggressive BRAF V600E mutation, similar to Dame Deborah James's case, has been approved for NHS use. The drug combination, trifluridine-tipiracil hydrochloride and bevacizumab, extends life by nearly a year for patients with no other treatment options, with some rare cases gaining up to seven more years. This approval is a significant step in fighting the incurable genetic form of bowel cancer, which often affects the young.